Dr. Francesca Cottini, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 58
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35.134163
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 58
- Services billed
- 209
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 91 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 23 | 16 |
| Hospital discharge day management, more than 30 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $489 in total to this clinician.
| Genzyme Corporation | $266 |
|---|---|
| Janssen Scientific Affairs, LLC | $150 |
| AstraZeneca UK Limited | $72.74 |
| Food and Beverage | $339 |
|---|---|
| Consulting Fee | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Aug 15, 2025 | Consulting Fee TALVEY · Oncology | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $60,624 in research payments for these studies, mostly to the institutions running them.
- Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Sanofi US Services Inc. · Recruiting · NCT04643002 - A Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistimab Alone versus Lenalidomide Alone in Participants with newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Ce…
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.